Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCR 6852

Next Previous
X
Search
Drug Profile

SCR 6852

Alternative Names: SCR-6852; SIM-0270

Latest Information Update: 07 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Simcere Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Preclinical Brain metastases

Most Recent Events

  • 23 Jul 2024 Simcere Pharmaceutical initiates phase-I pharmacokinetics trial (In Volunteers) in China (PO) (NCT06536036)
  • 05 Dec 2023 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 18 May 2022 Phase-I clinical trials in Breast cancer (Late-stage disease, Combination therapy, Metastatic disease) in China (PO) (NCT05293964)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top